Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 5/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.39 |
| ▸ | EGFR | P00533 | 9/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15876876 | 0.88 | TSPO (0.42) | KDREGFRTSPOPDPK1FYN | |
| SCHEMBL27532 | 0.87 | FYN (0.43) | KDREGFRTSPOFLT4FYN | |
| SCHEMBL29714497 | 0.87 | FYN (0.43) | KDREGFRTSPOFLT4FYN | |
| SCHEMBL16212933 | 0.84 | KDM4E (0.41) | TSPOFYN | |
| SCHEMBL24891 | 0.84 | TSPO (0.37) | KDREGFRTSPOFLT4FYN | |
| SCHEMBL30017773 | 0.84 | KDR (0.44) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL29229255 | 0.83 | TP53 (0.48) | KDREGFRFLT4FYNERBB2 | |
| SCHEMBL30505593 | 0.83 | TP53 (0.48) | KDREGFRFLT4FYNERBB2 | |
| SCHEMBL2950338 | 0.83 | EGFR (0.46) | KDREGFRERBB2HDAC3HDAC4 | |
| SCHEMBL16212409 | 0.82 | TSPO (0.38) | KDREGFRTSPOFLT4FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107556295-B | Quinazoline derivatives and process for their preparation | 正大天晴药业集团股份有限公司 | 2020-09-04 | — | — | CN | disclosed |
| EP-3050880-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-06-19 | — | — | EP | disclosed |
| EP-3081563-B1 | QUINAZOLINE DERIVATIVE AND SALTS THEREOF FOR USE IN THE TREATMENT OF CANCER | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2018-09-19 | — | — | EP | disclosed |
| US-9840494-B2 | Quinazoline derivative | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-12-12 | — | — | US | disclosed |
| US-9725439-B2 | Quinazoline derivative and preparation method therefor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-08-08 | — | — | US | disclosed |
| US-9556191-B2 | Aminoquinazoline derivatives and their salts and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| US-20160311796-A1 | QUINAZOLINE DERIVATIVE | TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD | 2016-10-27 | — | — | US | disclosed |
| EP-3081563-A1 | QUINAZOLINE DERIVATIVE | Tianjin Hemay Pharmaceutical Sci-tech Co. Ltd. (CN) | 2016-10-19 | — | — | EP | disclosed |
| EP-3050880-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2016-08-03 | — | — | EP | disclosed |
| US-20160214964-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-07-28 | — | — | US | disclosed |
| EP-2061773-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090111772-A1 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-04-30 | — | — | US | disclosed |
| WO-2009035718-A1 | TARTRATE SALTS OR COMPLEXES OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076022-A1 | epidermal growth factor receptor tyrosine kinase (EGFR-TK) and histone deacetylase inhibitors such as 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide, used as anticarcinogenic agents | CURIS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | CURIS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008033749-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076022-A1 | epidermal growth factor receptor tyrosine kinase (EGFR-TK) and histone deacetylase inhibitors such as 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide, used as anticarcinogenic agents | EGFR, HDAC1, HDAC8 | FLT1 1039/4885KDR 379/4885FGFR1 32/4885 |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | FLT1 3589/4885KDR 2667/4885FGFR1 768/4885 |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | HDAC1, HDAC8, EGFR | FLT1 1432/4885KDR 559/4885FGFR1 87/4885 |
| US-20160311796-A1 | QUINAZOLINE DERIVATIVE | NQO2, ABL1, HDAC6 | FLT1 4447/4885KDR 3786/4885FGFR1 3835/4885 |
| US-20090111772-A1 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | HDAC6, HDAC5, HDAC1 | FLT1 1332/4885KDR 305/4885FGFR1 83/4885 |
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC6 | FLT1 1077/4885KDR 360/4885FGFR1 40/4885 |
| US-20160214964-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | WEE1, WEE2, EGFR | FLT1 470/4885KDR 537/4885FGFR1 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.